News & Updates

Infusion of dexmedetomidine for 72 h and infusion rate at ≥1 mcg/kg/h appear to contribute to the development of fever in critically ill patients in a community teaching hospital, suggests a study.

The novel Pansy metal-free occluder shows promising efficacy and safety for managing atrial septal defect (ASD) in adults and children in a recent Chinese study.

In the treatment of moderate-to-severe plaque psoriasis, the investigational selective tyrosine kinase 2 (TYK2) inhibitor zasocitinib is associated with higher rates of skin clearance compared with the first-generation TYK2 inhibitor deucravacitinib, as shown in the head-to-head phase III LATITUDE Atlas trial.

Treatment with secukinumab results in improved clinical response at 12 months and is well tolerated in patients with hidradenitis suppurativa (HS), according to the ongoing SPECTRA study in France.

Topical ruxolitinib demonstrates significant clinical activity while having a favourable harms profile in the treatment of patients with cutaneous chronic graft-versus-host disease (cGVHD) in a phase II study.

In the treatment of patients with uncontrolled type 2 diabetes (T2D), adding empagliflozin to the combination of metformin plus evogliptin improves glycaemic control and other metabolic outcomes, as shown in a phase III study conducted in South Korea.

In patients with mild autonomous cortisol secretion (MACS), overnight metyrapone therapy helps to partially retore hypothalamic-pituitary-adrenal (HPA) axis balance and improve sleep and mood, with a favourable tolerability profile, according to a phase II trial.

Researchers from the Chinese University of Hong Kong (CUHK) have developed a novel molecule, BB56, which can potentially serve as a lead compound for the development of new drugs for neuroinflammatory disorders.